Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company. It engages in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. The company is headquartered in Torrance, CA.

Company profile
Ticker
EMMA
Exchange
Website
CEO
Yutaka Niihara
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
MYnd Analytics, Inc., CNS RESPONSE, INC., STRATIVATION, INC.
SEC CIK
Corporate docs
Subsidiaries
EMI Holding, Inc. • Emmaus Medical, Inc. • Emmaus Medical Japan, Inc. • Newfield Nutrition Corporation • Emmaus Medical Europe Limited • Emmaus Life Sciences, Co. Ltd. • EJ Holdings, Inc. ...
IRS number
870419387
EMMA stock data
Press releases
Emmaus Life Sciences Reports Q1 2022 Financial Results and Provides Business Update
13 May 22
Emmaus Life Sciences to Present at Investor Conferences in May
26 Apr 22
Emmaus Life Sciences Announces Launch of Full-Service Telehealth Solution
11 Apr 22
Emmaus Life Sciences Presented Positive Real-World Data on the Efficacy of Endari® in Preventing Acute Complications from Sickle Cell Disease at the 62nd Annual Scientific Meeting of the British Society for Haematology
7 Apr 22
Investment data
Securities sold
Number of investors
Calendar
1 Jul 22
2 Jul 22
31 Dec 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Sep 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 813K | 813K | 813K | 813K | 813K | 813K |
Cash burn (monthly) | 488.67K | 245.5K | 1.02M | 882.08K | 1.58M | 165.5K |
Cash used (since last report) | 1.5M | 753.03K | 3.14M | 2.71M | 4.84M | 507.64K |
Cash remaining | -685.9K | 59.97K | -2.32M | -1.89M | -4.03M | 305.36K |
Runway (months of cash) | -1.4 | 0.2 | -2.3 | -2.1 | -2.6 | 1.8 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 May 22 | Lee Willis C | Common stock, $0.001 par value | Buy | Acquire P | No | No | 0.4 | 2,500 | 1K | 283,774 |
27 May 22 | Lee Willis C | Common stock, $0.001 par value | Buy | Acquire P | No | No | 0.37 | 2,500 | 925 | 281,274 |
23 May 22 | Niihara Yutaka | Common stock, $0.001 par value | Buy | Acquire P | No | No | 0.5 | 2,000 | 1K | 11,333,857 |
20 May 22 | Niihara Yutaka | Common stock, $0.001 par value | Buy | Acquire P | No | No | 0.49 | 5,000 | 2.45K | 11,331,857 |
18 May 22 | Niihara Yutaka | Common stock, $0.001 par value | Buy | Acquire P | No | No | 0.35 | 7,351 | 2.57K | 11,326,857 |
13 May 22 | Niihara Yutaka | Common stock, $0.001 par value | Buy | Acquire P | No | No | 0.34 | 10,000 | 3.4K | 11,319,506 |
9 May 22 | Niihara Yutaka | Common stock, $0.001 par value | Buy | Acquire P | No | No | 0.6 | 6,000 | 3.6K | 11,309,506 |
11 Apr 22 | Lee Willis C | Common stock, $0.001 par value | Buy | Acquire P | No | No | 0.88 | 8,900 | 7.83K | 278,774 |
8 Apr 22 | Lee Willis C | Common stock, $0.001 par value | Buy | Acquire P | Yes | No | 0.76 | 1,600 | 1.22K | 241,194 |
6 Apr 22 | Lee Willis C | Common stock, $0.001 par value | Buy | Acquire P | Yes | No | 0.95 | 1,400 | 1.33K | 239,594 |
Institutional ownership, Q3 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0 |
Total shares | 0 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Financial report summary
?Risks
- We have operated at a loss and may continue to operate at a loss for the foreseeable future.
- We are dependent on financing to sustain our operations, and there is substantial doubt regarding our ability to continue as a going concern.
- We are dependent on the commercial success of our only approved product, Endari®.
- We may expend our limited resources to pursue a product candidate or indication and fail to capitalize on product candidates or indications for which there is a greater likelihood of commercial success.
- We face intense competition from companies with greater resources than us, and if our competitors are successful in marketing or develop alternative treatments our commercial opportunities may be reduced or eliminated.
- If we are unable to achieve and maintain adequate levels of coverage and reimbursement for Endari®, on reasonable pricing terms, its commercial success may be severely hindered.
- The majority of Endari® sales are to a few customers and loss of a customer could adversely affect our results of operations.
- The market exclusivity for SCD in the U.S. is limited and Endari® will have no market exclusivity in the United Arab Emirates, where it was recently approved for marketing, or other countries in the Middle East North Africa (MENA) region where applications for marketing approval are pending, which lack of exclusivity could adversely affect the commercial success of Endari®.
- Many of our potential customers are in markets with underdeveloped health care systems.
- A variety of risks associated with marketing Endari® internationally could hurt our business.
- We may not be able to anticipate the demand for and appropriate supply of Endari®.
- If the L-glutamine manufacturer upon which we rely fails to produce in the volumes and quality that we require on a timely basis or fails to comply with stringent regulations applicable to pharmaceutical manufacturers, we may face interruptions in the commercialization of, or be unable to meet demand for, our L- glutamine based products, and may lose any marketing exclusivity and potential revenues.
- Endari® may cause undesirable side effects or have other unexpected properties that could result in post-approval regulatory action.
- The use of any of our product candidates in clinical trials and in the market may expose us to liability claims.
- We will need to increase the size and complexity of our organization in the future, and we may experience difficulties in managing our growth and executing our growth strategy.
- We rely heavily on Yutaka Niihara, M.D., M.P.H., our Chairman and Chief Executive Officer, and the loss of his services would have a material adverse effect upon our business and prospects.
- Our business and operations may be adversely affected by information technology (“IT”) system failures or cybersecurity or data breaches.
- Historical material weaknesses in our internal controls over financial reporting have not been fully remediated.
- We may not be able to obtain and enforce intellectual property rights that cover our commercial activities or are sufficient to prevent third parties from competing against us.
- We depend on licenses of certain patents for the development of some of our product candidates. If any of these licenses terminate, or if any of the licensed patents is successfully challenged, we may be unable to continue the development of the affected product candidates.
- If we are unable to protect proprietary technology that we invent and develop, we may not be able to compete effectively, and our business and financial prospects may be harmed.
- Endari® is subject to ongoing and continued regulatory review, compliance with which may result in significant expense and limit our ability to commercialize Endari®.
- We may not be able to receive regulatory approval of PGLG treatment for diverticulosis or other indications, which would adversely affect our financial and operating condition.
- The development process to obtain FDA approvals for new drugs therapies is very costly and time consuming and if we cannot complete our clinical trials in a cost-effective manner, our operations may be adversely affected.
- We may not be able to complete clinical trial programs for any of our product candidates successfully within any specific time period or at all, and if such clinical trials take longer to complete than we project, our ability to execute our current business strategy will be adversely affected.
- We may be required to suspend, repeat or terminate our clinical trials if they do not meet regulatory requirements, the results are negative or inconclusive, human subject protections are inadequate, the trials are not well designed, or clinical investigators fail to comply with all requirements for the conduct of trials under the applicable IND, any of which may result in significant negative repercussions on our business and financial condition.
- Changes in regulatory requirements and guidance or unanticipated events during our clinical trials may occur, which may result in necessary changes to clinical trial protocols, informed consents and clinical trial budgets, any of which changes could result in increased costs to us, delay our development timeline or reduce the likelihood of successful completion of the clinical trial.
- There are various uncertainties related to the research, development and commercialization of Kainos’s KM10544 IRAK4 inhibitor to treat cancers and the cell sheet engineering regenerative medicine products we are developing which could negatively affect our ability to commercialize such products.
- Health care reform measures and changes in policies, funding, staffing and leadership at the FDA and other agencies could hinder or prevent the commercial success of Endari®.
- If we fail to comply with federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.
- Even though we have obtained Orphan Drug designation for Endari®, we may not be able to maintain Orphan Drug marketing exclusivity for Endari®or any of our other product candidates.
- Any product candidate for which we obtain marketing approval would be subject to post-marketing regulatory requirements and limitations and could be subject to recall or withdrawal from the market, and we may be subject to penalties if we fail to comply with such regulatory requirements or if we experience unanticipated problems in commercializing any of our product candidates, when and if any of them are approved by regulators.
- Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of our product candidates and then commercialize them as products and affect the prices we may obtain.
- EJ Holdings has no revenues and is dependent on us to fund its business and operations, and there is no assurance that we can continue to provide needed funding or that EJ Holdings will be able to continue its activities.
- EJ Holdings is subject to risks inherent in a new business and may not be successful.
- We do not control EJ Holdings, and EJ Holdings may engage in activities contrary to our best interests.
- EJ Holdings retains discretion over its use of any funds that we provide to it.
- We have been delinquent in our past SEC reporting obligations and if we fail to timely file our future SEC reports, our security holders and prospective investors will not have current information regarding our financial statements and status of our business and operations and our common stock may no longer be eligible for quotation on the OTC Markets Group, Inc.
- Stockholders may experience future dilution from future equity offerings.
- A substantial number of shares of common stock may be sold in the market, which may depress the market price for our common stock.
- We may issue preferred stock in the future, and the terms of the preferred stock may reduce the value of our common stock.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
acid, acute, adapt, affiliate, Africa, Arabia, arrangement, Asembia, attain, augment, Bahrain, billion, binominal, comply, constituted, Cooperation, Council, COVID, cumulative, deemed, doubt, East, employment, encourage, enterprise, environmental, ERP, exceed, Exhibit, expansion, favorable, force, GCC, governmental, Gulf, incorporated, inhibited, IP, Kingdom, liquidity, margin, Masaharu, met, Middle, Ministry, online, Osato, outcome, outdated, owner, pending, plant, portal, previously, primary, profit, profitability, profitable, purpose, recommendation, redeemable, referenced, region, remotely, repayment, replace, resource, retail, retrofitting, retrospect, satisfy, Saudi, settle, settlement, shortfall, shuttered, solution, Soomi, Standard, strategic, subscribing, supplier, sustain, sustainable, telehealth, traditional, uncertainty, UpScript, visit, web, wife, Yutaka
Removed:
acceptable, accredited, Aid, amendment, amounted, annum, antidilution, applied, assumed, auditing, award, began, binomial, blood, bound, calculated, case, characteristic, commenced, continuance, curtailing, designation, Economic, efficacy, embedded, entering, entirety, European, exclusivity, extend, foreign, forgivable, forgiven, gain, grant, identified, implement, investee, investigation, kilogram, large, launch, limited, Lincoln, long, marketable, measure, mechanism, minimal, MOA, newly, Nutrition, optionee, organization, Park, Paycheck, payroll, periodic, pharmacokinetic, PPP, prepayable, pricing, producer, proof, Protection, qualifying, ratio, reclassified, reduced, relied, Relief, responsible, restate, restricted, resulted, safety, selection, specific, subsequently, surviving, temporary, therapeutic, transfer, transferee, unamortized, underway, Union, unrestricted, upgrading, vendor, vest, vested, yield
Current reports
8-K
Departure of Directors or Certain Officers
10 Jun 22
8-K
Emmaus Life Sciences Reports Q1 2022 Financial Results and Provides Business Update
13 May 22
8-K
Emmaus Life Sciences Reports 2021 Financial Results and Provides Business Update
31 Mar 22
8-K
Departure of Directors or Certain Officers
10 Jan 22
8-K
Departure of Directors or Certain Officers
29 Nov 21
8-K
Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine
12 Oct 21
8-K
Emmaus Life Sciences Provides SEC Reporting Update
9 Aug 21
8-K
Other Events
19 May 21
8-K
Entry into a Material Definitive Agreement
22 Feb 21
8-K
Entry into a Material Definitive Agreement
16 Feb 21
Registration and prospectus
D
$220K in equity, sold $110K, 1 investor
30 Jun 22
S-8
Registration of securities for employees
30 Dec 21
D
$17M in other securities, sold $1.92M, 10 investors
16 Feb 21
D/A
$3.84M in options, sold $3.84M, 18 investors
9 Oct 20
D/A
$3.68M in options, sold $3.68M, 18 investors
7 Oct 20
D
$3.68M in options, 18 investors
7 Oct 20
D
$1.9M in options, sold $947.6K, 18 investors
7 Aug 20
424B5
Prospectus supplement for primary offering
3 Mar 20
25-NSE
Exchange delisting
8 Nov 19
424B5
Prospectus supplement for primary offering
25 Oct 19
Other
EFFECT
Notice of effectiveness
12 Jun 19
CORRESP
Correspondence with SEC
10 Jun 19
UPLOAD
Letter from SEC
29 May 19
CORRESP
Correspondence with SEC
8 May 19
UPLOAD
Letter from SEC
1 May 19
UPLOAD
Letter from SEC
24 Feb 19
EFFECT
Notice of effectiveness
24 Dec 18
CORRESP
Correspondence with SEC
19 Dec 18
UPLOAD
Letter from SEC
19 Dec 18
EFFECT
Notice of effectiveness
2 Jul 18
Ownership
4
Emmaus Life Sciences / WILLIS C LEE ownership change
3 Jun 22
4
Emmaus Life Sciences / Yutaka Niihara ownership change
2 Jun 22
4
Emmaus Life Sciences / Yutaka Niihara ownership change
19 May 22
4
Emmaus Life Sciences / WILLIS C LEE ownership change
12 Apr 22
4
Emmaus Life Sciences / Yutaka Niihara ownership change
2 Mar 22
4
Emmaus Life Sciences / WILLIS C LEE ownership change
28 Feb 22
4
Emmaus Life Sciences / Yutaka Niihara ownership change
28 Feb 22
4
Emmaus Life Sciences / Yutaka Niihara ownership change
23 Feb 22
4
Emmaus Life Sciences / Yutaka Niihara ownership change
18 Feb 22
SC 13D/A
Emmaus Life Sciences / Niihara Yutaka ownership change
16 Feb 22